---
layout: report
type: daily
topic_slug: multiple_myeloma
topic_display: "Multiple Myeloma"
date: 2025-08-19
run_id: multiple_myeloma_20250819_090935
theme: "Decoding Your Myeloma: FISH Genetics and R-ISS Staging"
persona: "Persona.INFORMED_PATIENT"
source_plan_path: "/home/runner/work/health_buddy_app/health_buddy_app/.results/multiple_myeloma/weekly_plan/2025-08-18/plan.json"
permalink: /topics/multiple_myeloma/daily/2025-08-19/multiple_myeloma_20250819_090935/
title: "Multiple Myeloma â€” 2025-08-19"
---

# Decoding Your Myeloma: FISH Genetics and R-ISS Staging

Understanding your multiple myeloma diagnosis goes beyond just the name. Two crucial elements, FISH genetics and the Revised International Staging System (R-ISS), provide deeper insight into your specific myeloma, guiding treatment and offering a clearer prognosis. For the informed patient, decoding these aspects is key to proactive participation in your care.

**Fluorescence In Situ Hybridization (FISH) Genetics: Your Myeloma's Unique Fingerprint**

FISH testing analyzes chromosomes in your myeloma cells for specific genetic abnormalities. These aren't inherited; they're changes occurring within the cancer cells. Knowing these abnormalities is vital because certain changes are linked to how aggressive your myeloma might be and how it responds to different therapies.

Common high-risk FISH abnormalities include del(17p), t(4;14), and t(14;16). If your report shows one, your myeloma might be more aggressive, often benefiting from intensive treatments from the outset. This can involve combinations of drugs like proteasome inhibitors (e.g., bortezomib, carfilzomib), immunomodulatory drugs (e.g., lenalidomide, pomalidomide), and CD38 antibodies (e.g., daratumumab, isatuximab). Conversely, abnormalities like hyperdiploidy (extra chromosomes) are often associated with a better prognosis.

**How to Read Your FISH Report:** Your report lists chromosomal aberrations and their percentage. A positive finding, like "del(17p) detected in 60% of plasma cells," indicates a significant presence. Ask your doctor:
*   "How do these specific FISH findings (e.g., del(17p)) influence my *induction* therapy choices?"
*   "Are there specific *maintenance* therapies more effective given my genetic profile?"
*   "Will these tests be *re-evaluated* during my treatment, and if so, how often?"

**Revised International Staging System (R-ISS): A Comprehensive Prognostic Tool**

The R-ISS refines staging by combining traditional clinical markers with high-risk FISH abnormalities (like del(17p)) and elevated lactate dehydrogenase (LDH). This system provides a more accurate prognosis.

*   **Clinical Markers Explained:**
    *   **Albumin:** Reflects overall health and kidney function.
    *   **Beta-2 Microglobulin:** Often correlates with tumor burden and kidney function.
    *   **LDH (Lactate Dehydrogenase):** Can indicate faster disease growth or aggressiveness.

*   **R-ISS Stage I:** Standard-risk genetics, normal LDH, and normal albumin/beta-2 microglobulin.
*   **R-ISS Stage II:** Cases not fitting Stage I or III, encompassing a range of prognoses.
*   **R-ISS Stage III:** High-risk cytogenetics (e.g., del(17p), t(4;14), t(14;16)) OR elevated LDH, plus high beta-2 microglobulin. This suggests a more aggressive disease course.

**Practical Guidance:** Understanding your R-ISS stage and FISH results empowers informed discussions. For R-ISS Stage III, doctors might recommend earlier or more aggressive therapies, including stem cell transplant, or exploring novel agents like bispecific antibodies or CAR T-cell therapy in specific high-risk scenarios.

By actively engaging with your FISH genetics and R-ISS staging, you become an integral part of your treatment team, making informed decisions tailored to your unique myeloma journey. This knowledge is a powerful tool in navigating your path forward.
